Tardive Dyskinesia Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “Tardive Dyskinesia Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Tardive Dyskinesia pipeline landscape. It covers the Tardive Dyskinesia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Tardive Dyskinesia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Tardive Dyskinesia Pipeline Report
- DelveInsight’s Tardive Dyskinesia pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Tardive Dyskinesia treatment.
- The leading companies working in the Tardive Dyskinesia Market include Addex Therapeutics, Contera Pharma, Teva Pharmaceutical, SOM Biotech, Mitsubishi Tanabe Pharma, and others.
- Promising Tardive Dyskinesia Pipeline Therapies in the various stages of development include MT-5199, Valbenazine, SD-809, NBI-98854, NBI-98854, and others.
- November 2023: Neurocrine Biosciences announced a study of Phase 4 clinical trials for Valbenazine. This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.
- September 2023: Mitsubishi Tanabe Pharma Corporation announced a study of Phase 2 & 3 clinical trials for MT-5199. The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Request a sample and discover the recent advances in Tardive Dyskinesia Treatment Drugs @ Tardive Dyskinesia Pipeline Report
In the Tardive Dyskinesia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tardive dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Tardive Dyskinesia Overview
Tardive dyskinesia (TD) is a syndrome that encompasses a constellation of iatrogenic movement disorders caused by antagonism of dopamine receptors. The movement disorders include akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other abnormal involuntary movements. Most often, these dyskinetic disorders precipitate following chronic antipsychotic administration, however, several other medications are also associated with tardive dyskinesia.
Find out more about Tardive Dyskinesia Therapeutics Assessment @ Tardive Dyskinesia Preclinical and Discovery Stage Products
Tardive Dyskinesia Emerging Drugs Profile
- SOM3366: SOM Biotech
Tardive Dyskinesia Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the Tardive dyskinesia therapies. The Tardive dyskinesia companies which have their Tardive dyskinesia drug candidates in the most advanced stage, i.e Phase III include, Mitsubishi Tanabe Pharma.
DelveInsight’s Tardive Dyskinesia pipeline report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Tardive dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
Tardive Dyskinesia Pipeline Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging Tardive Dyskinesia Pipeline Therapies @ Tardive Dyskinesia Clinical Trials Assessment
Scope of the Tardive Dyskinesia Pipeline Report
- Coverage- Global
- Tardive Dyskinesia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Tardive Dyskinesia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Tardive Dyskinesia Companies- Addex Therapeutics, Contera Pharma, Teva Pharmaceutical, SOM Biotech, Mitsubishi Tanabe Pharma, and others.
- Tardive Dyskinesia Pipeline Therapies- MT-5199, Valbenazine, SD-809, NBI-98854, NBI-98854, and others.
Dive deep into rich insights for new drugs for Tardive Dyskinesia Treatment, Visit @ Tardive Dyskinesia Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Tardive dyskinesia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Tardive dyskinesia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Deutetrabenazine: Teva Pharmaceutical
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- MT-5199: Mitsubishi Tanabe Pharma
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- CP-011: Contera Pharma
- Drug profiles in the detailed report…..
- Inactive Products
- Tardive dyskinesia Key Companies
- Tardive dyskinesia Key Products
- Tardive dyskinesia- Unmet Needs
- Tardive dyskinesia- Market Drivers and Barriers
- Tardive dyskinesia- Future Perspectives and Conclusion
- Tardive dyskinesia Analyst Views
- Tardive dyskinesia Key Companies
- Appendix
For further information on the Tardive Dyskinesia Pipeline therapeutics, reach out to Tardive Dyskinesia Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/tardive-dyskinesia-market
